HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Keiji Hasumi Selected Research

SMTP 7

12/2018Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys.
12/2018Reduction of Ischemia Reperfusion-Related Brain Hemorrhage by Stachybotrys Microspora Triprenyl Phenol-7 in Mice With Antioxidant Effects.
11/2018Antineuroinflammatory Effect of SMTP-7 in Ischemic Mice.
1/2018Evaluation of the effects of a new series of SMTPs in the acetic acid-induced embolic cerebral infarct mouse model.
11/2015Structure-activity relationships of the plasminogen modulator SMTP with respect to the inhibition of soluble epoxide hydrolase.
12/2014Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.
8/2014SMTP-7, a new thrombolytic agent, decreases hemorrhagic transformation after transient middle cerebral artery occlusion under warfarin anticoagulation in mice.
6/2014Mechanism of the action of SMTP-7, a novel small-molecule modulator of plasminogen activation.
2/2014SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates.
1/2014Altered gene expression in an embolic stroke model after thrombolysis with tissue plasminogen activator and Stachybotrys microspora triprenyl phenol-7.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Keiji Hasumi Research Topics

Disease

10Inflammation (Inflammations)
05/2022 - 01/2011
9Infarction (Infarctions)
12/2018 - 01/2010
8Cerebral Infarction
01/2018 - 01/2010
7Ischemic Stroke
01/2021 - 02/2014
5Stroke (Strokes)
12/2018 - 07/2011
5Neoplasms (Cancer)
06/2012 - 02/2004
4Ischemia
12/2018 - 09/2010
4Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
12/2018 - 08/2014
4Embolic Stroke
12/2018 - 04/2011
4Cerebral Hemorrhage
12/2014 - 09/2010
3Hemorrhage
01/2021 - 01/2018
3Edema (Dropsy)
12/2018 - 09/2010
3Thrombosis (Thrombus)
01/2012 - 05/2009
3Pulmonary Embolism
01/2012 - 04/2002
2Body Weight (Weight, Body)
12/2020 - 01/2012
2Neurologic Manifestations (Neurological Manifestations)
12/2018 - 02/2014
2Brain Ischemia (Cerebral Ischemia)
12/2018 - 10/2011
2Thrombotic Stroke
06/2014 - 02/2014
2Embolism (Embolus)
01/2014 - 01/2010
2Thyroid Neoplasms (Thyroid Cancer)
06/2012 - 01/2012
2Hemangiosarcoma (Angiosarcoma)
10/2008 - 12/2007
1Acute Kidney Injury (Acute Renal Failure)
11/2021
1Hyperalgesia
12/2020
1Diabetic Neuropathies (Diabetic Neuropathy)
12/2020
1Intracranial Hemorrhages (Intracranial Hemorrhage)
12/2018
1IGA Glomerulonephritis (IGA Nephropathy)
06/2012
1Fibrosis (Cirrhosis)
06/2012
1Reperfusion Injury
10/2011
1Brain Injuries (Brain Injury)
10/2011
1Vascular System Injuries
09/2010

Drug/Important Bio-Agent (IBA)

17SMTP 7IBA
12/2018 - 09/2010
8Tissue Plasminogen Activator (Alteplase)FDA Link
12/2018 - 01/2010
6Epoxide HydrolasesIBA
01/2021 - 12/2014
5PlasminogenIBA
01/2021 - 01/2012
5Phenol (Carbolic Acid)FDA Link
12/2018 - 01/2010
4AntioxidantsIBA
11/2021 - 01/2018
4Pharmaceutical PreparationsIBA
01/2021 - 02/2014
4Neuroprotective AgentsIBA
12/2018 - 10/2011
4Acetic Acid (Vinegar)FDA LinkGeneric
01/2018 - 01/2010
3FibrinolysinFDA Link
01/2018 - 02/2004
3Fibrinolytic Agents (Antithrombotic Agents)IBA
08/2014 - 04/2011
23-nitrotyrosineIBA
12/2018 - 10/2011
2Carmine (Natural Red 4)IBA
06/2012 - 01/2012
2Hyaluronan ReceptorsIBA
06/2012 - 01/2011
2Troglitazone (Rezulin)FDA Link
10/2008 - 12/2007
1Glucose (Dextrose)FDA LinkGeneric
05/2022
1Blood Glucose (Blood Sugar)IBA
12/2020
1EnzymesIBA
12/2019
1CollagenIBA
12/2018
1EdaravoneIBA
12/2018
1Caspase 3 (Caspase-3)IBA
12/2018
1NucleotidesIBA
11/2018
1SMTP 6IBA
01/2018
1Warfarin (Coumadin)FDA LinkGeneric
08/2014
1TenascinIBA
06/2012
1lac dyeIBA
06/2012
1nivalenolIBA
06/2012
1Immunoglobulin A (IgA)IBA
06/2012
1Plasminogen Activators (Plasminogen Activator)IBA
01/2012
1Drinking WaterIBA
01/2012
1NitrosaminesIBA
01/2012
1SulfadimethoxineIBA
01/2012
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
10/2011
1Superoxides (Superoxide)IBA
10/2011
14-hydroxy-2-nonenal (4-hydroxynonenal)IBA
07/2011
1Reactive Oxygen Species (Oxygen Radicals)IBA
07/2011
1Peroxynitrous Acid (Peroxynitrite)IBA
04/2011
1Therapeutic UsesIBA
04/2011
1Serine Proteases (Serine Protease)IBA
01/2011
1Hemostatics (Antihemorrhagics)IBA
09/2010
1Messenger RNA (mRNA)IBA
09/2010
1CytokinesIBA
09/2010
1triphenyltetrazoliumIBA
01/2010
1ThrombinFDA Link
05/2009
1Prothrombin (Factor II)IBA
05/2009
1Urethane (Ethyl Carbamate)IBA
10/2008
12,4-thiazolidinedione (thiazolidinedione)IBA
10/2008
1Insulin (Novolin)FDA Link
10/2008
1OligonucleotidesIBA
12/2007
1epigallocatechin gallate (epigallocatechin-3-gallate)IBA
09/2004
1Hydroxyl RadicalIBA
09/2004
1estropipate (Ogen)FDA LinkGeneric
02/2004
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
04/2002
1surfactin peptideIBA
04/2002

Therapy/Procedure

3Therapeutics
12/2014 - 04/2011
1Thrombolytic Therapy
12/2014
1Sutures (Suture)
08/2014
1Intravenous Infusions
02/2014
1Injections
01/2012
1Intraperitoneal Injections
01/2012